Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback
CMPX•FDA feedback on tovecimig
Sept. 22 (Reuters) - Compass Therapeutics Inc. CMPX.O:
- Compass Therapeutics provides regulatory update on tovecimig in biliary tract cancer following FDA feedback.
- The FDA recommends a survival benefit trial before BLA submission for tovecimig.
- Compass Therapeutics does not believe a new trial is warranted before BLA submission for tovecimig.
- The company plans to further engage with the FDA on BLA submission for tovecimig.
- Compass Therapeutics remains confident in tovecimig based on significant ORR and PFS improvements.
